Description
UDP is the diphosphate of the nucleoside uridine. It is a specific agonist of the P2Y purinoceptor P2Y6 (EC50 = 13 nM for human P2Y6), stimulating the production of inflammatory mediators, phagocytosis, and vasoconstriction.1,2,3,4,5,6 UDP also acts as an antagonist of P2Y14, whose agonists include UDP-glucose (Item No. 15602), UDP-galactose, and UDP-glucuronic acid.1,2WARNING This product is not for human or veterinary use.
References
[1] KENNETH A JACOBSON. Development of selective agonists and antagonists of P2Y receptors.[J]. Purinergic Signalling, 2009, 5 1: 75-89. DOI:
10.1007/s11302-008-9106-2[2] MARIA P ABBRACCHIO. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.[J]. Pharmacological Reviews, 2006, 58 3: 281-341. DOI:
10.1124/pr.58.3.3[3] RICARDO A GARCIA. P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion development.[J]. PLoS ONE, 2014: e111385. DOI:
10.1371/journal.pone.0111385[4] INOUE K. UDP facilitates microglial phagocytosis through P2Y6 receptors.[J]. Cell Adhesion & Migration, 2007, 1 3: 131-132. DOI:
10.4161/cam.1.3.4937[5] PEDRO BESADA. Structure−Activity Relationships of Uridine 5‘-Diphosphate Analogues at the Human P2Y6 Receptor[J]. Journal of Medicinal Chemistry, 2006, 49 18: 5532-5543. DOI:
10.1021/jm060485n[6] CALLUM MITCHELL. Identification of contractile P2Y1, P2Y6, and P2Y12 receptors in rat intrapulmonary artery using selective ligands.[J]. Journal of Pharmacology and Experimental Therapeutics, 2012, 343 3: 755-762. DOI:
10.1124/jpet.112.198051
